Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

N/A
1(50.0%)
Phase 2
1(50.0%)
2Total
N/A(1)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT06010576Not ApplicableRecruiting

Endoscopic Ultrasound-guided Rendezvous Versus Precut Papillotomy

Role: collaborator

NCT07292207Phase 2Not Yet Recruiting

Abemaciclib for Molecular Residual Disease Detected by Circulating Tumor DNA in HR+/HER2- Early Breast Cancer

Role: collaborator

NCT04706234Recruiting

Systematic Assessment of Laryngopharyngeal Function in Patients With Neurodegenerative Diseases

Role: collaborator

All 3 trials loaded